CD274 and non-small cell lung carcinoma: In a study evaluating KN046 in combination with axitinib in advanced NSCLC (NCT05420220), for previously untreated patients with PD-L1 TPS ≥1% and patients treated with CPIs, the ORR after receiving the combination therapy was 56.8% and 9.4% respectively, and the DCR was 90.9% and 81.3%, showing promising efficacy (98).